Illuccix is the first and only PSMA-PET imaging agent to have...

Illuccix is the first and only PSMA-PET imaging agent to have been granted regulatoryapproval in Canada. Health Canada became the third regulatory body worldwide to approveIlluccix, which is also commercially available in Australia, New Zealand and the UnitedStates. Dr. Philip Cohen, INITIO Director and Division Head, Nuclear Medicine, Lions GateHospital in North Vancouver said, "Nuclear isotope therapy enters a new era with theability to see and diagnose invisible cancers based on their molecular "signature" andthen target them based on the same signature. Now if we can see the cancer we can treatit, and potentially control, and eventually someday cure this terrible disease." Andr? Gagnon, President of Isologic added, "PSMA-PET is emerging as a standard of careworldwide, and it is tremendous that we can now provide Canadian physicians and theirpatients with this innovative new diagnostic tool via our national network, servicing 265hospitals and clinics." Kevin Richardson, Chief Executive Officer for Telix Americas continued, "The launch ofIlluccix in Canada marks an important milestone for Telix and the 24,000 men who will bediagnosed with prostate cancer in the country this year.([1]) Widespread availability ofPSMA-PET imaging, via Telix's distribution partner Isologic, will help deliver on asignificant unmet medical need for the men in Canada and their families affected by thisdisease."